This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Eletriptan hydrobromide, Relert (Portugal)
Description: RELPAX contains Eletriptan hydrobromide, which is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist that acts at serotonin 5HT1B receptors on intracranial blood vessels and 5HT1D receptors on sensory nerve endings to relieve the pain and associated symptoms of a migraine attack.
Migraine headaches are believed to be the result of abnormal activity in the brain that leads to dilation of the blood vessels on the surface of the brain as well as the tissues that surround the brain. The dilation of the blood vessels is believed to be associated with inflammation. The triptan class of drugs, including eletriptan, constricts the blood vessels, thus preventing migraine headache. While it is very effective in relieving migraine, it does not prevent or reduce the number of attacks of migraine.
Pink Sheet Relpax FDA Reviewers
Pink Sheet Relpax Clinical Development
Pink Sheet Relpax price
Additional information available to subscribers only: